BR112018069785A2 - formas de dosagem dissuasivas de abuso de liberação prolongada - Google Patents

formas de dosagem dissuasivas de abuso de liberação prolongada

Info

Publication number
BR112018069785A2
BR112018069785A2 BR112018069785A BR112018069785A BR112018069785A2 BR 112018069785 A2 BR112018069785 A2 BR 112018069785A2 BR 112018069785 A BR112018069785 A BR 112018069785A BR 112018069785 A BR112018069785 A BR 112018069785A BR 112018069785 A2 BR112018069785 A2 BR 112018069785A2
Authority
BR
Brazil
Prior art keywords
dosage forms
dissuasive
prolonged release
release abuse
controlled release
Prior art date
Application number
BR112018069785A
Other languages
English (en)
Inventor
Nichols Gary
Park Jaehan
Schallom John
Gaik Jonathan
Lathrop Ryan
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of BR112018069785A2 publication Critical patent/BR112018069785A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

a presente invenção refere-se a formas de dosagem dissuasivas de abuso e liberação prolongada que compreendem partículas de liberação controlada resistentes ao esmagamento que proveem propriedades dissuasivas de abuso às formas de dosagem. as partículas de liberação controlada resistentes ao esmagamento, que compreendem polímeros plásticos/elásticos e pelo menos um ingrediente farmacêutico ativo (api) ou um sal farmaceuticamente aceitável deste, são preparadas por um processo de extrusão por fusão a quente.
BR112018069785A 2016-03-31 2017-03-21 formas de dosagem dissuasivas de abuso de liberação prolongada BR112018069785A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315952P 2016-03-31 2016-03-31
PCT/US2017/023316 WO2017172406A1 (en) 2016-03-31 2017-03-21 Extended release, abuse deterrent dosage forms

Publications (1)

Publication Number Publication Date
BR112018069785A2 true BR112018069785A2 (pt) 2019-01-29

Family

ID=59958479

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069785A BR112018069785A2 (pt) 2016-03-31 2017-03-21 formas de dosagem dissuasivas de abuso de liberação prolongada

Country Status (8)

Country Link
US (3) US10624888B2 (pt)
EP (1) EP3435984A4 (pt)
JP (2) JP7023859B2 (pt)
AU (1) AU2017241266B2 (pt)
BR (1) BR112018069785A2 (pt)
CA (1) CA3019335A1 (pt)
MX (1) MX2018011799A (pt)
WO (1) WO2017172406A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3435984A4 (en) * 2016-03-31 2019-11-06 SpecGx LLC MISUSE OF INFACTIOUS PHARMACEUTICAL FORMATION WITH DELAYED RELEASE
BE1025649B1 (fr) * 2017-08-25 2019-05-20 Eleonor Sprl Composition comprenant au moins un alcaloïde de protoberbérine et son procédé de fabrication
WO2020068510A1 (en) * 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
BE1028182B1 (fr) * 2020-04-17 2022-03-28 Eleonor Composition comprenant au moins un alcaloïde de protoberbérine et son procédé de fabrication
CN114073252B (zh) * 2020-08-12 2022-11-08 中国热带农业科学院环境与植物保护研究所 荔枝用展着剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
DE20308437U1 (de) 2002-04-05 2003-11-13 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
SG169334A1 (en) * 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt) * 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3435984A4 (en) * 2016-03-31 2019-11-06 SpecGx LLC MISUSE OF INFACTIOUS PHARMACEUTICAL FORMATION WITH DELAYED RELEASE

Also Published As

Publication number Publication date
JP7366170B2 (ja) 2023-10-20
JP2022051901A (ja) 2022-04-01
AU2017241266B2 (en) 2022-02-10
JP2019510040A (ja) 2019-04-11
US11446293B2 (en) 2022-09-20
CA3019335A1 (en) 2017-10-05
US20200268747A1 (en) 2020-08-27
JP7023859B2 (ja) 2022-02-22
US20170281615A1 (en) 2017-10-05
EP3435984A1 (en) 2019-02-06
US10624888B2 (en) 2020-04-21
AU2017241266A1 (en) 2018-10-18
EP3435984A4 (en) 2019-11-06
MX2018011799A (es) 2019-01-24
WO2017172406A1 (en) 2017-10-05
US20230079134A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
BR112018069785A2 (pt) formas de dosagem dissuasivas de abuso de liberação prolongada
EP3519011A4 (en) SYSTEMS, DEVICES AND METHODS FOR MEDICATION INJECTION AND DISEASE MANAGEMENT
EP3309177A4 (en) Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
WO2017205844A3 (en) Materials architecture for gastric residence systems
PE20160606A1 (es) Formas de dosificacion granuladas disuasivas del abuso de liberacion inmediata
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
EP3412292A4 (en) USE OF METHOXATIN, DERIVATIVE AND / OR SALT OF SJÖGREN SYNDROME AND PHARMACEUTICAL COMPOSITION
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais
MA42458A (fr) Systèmes améliorés d'administration de nanoparticules
PH12018501758A1 (en) Oritavancin formulations
BR112016017644A2 (pt) conjugados de fator vii
WO2017079403A3 (en) Polymeric nanoparticles
BR112018010767A2 (pt) revestimento comestível, sistema de produtos comestíveis apresentando o referido revestimento comestível e uso do referido sistema
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
FR3019047B1 (fr) Diffuseur d'agent parfumant et/ou assainissant active par retournement.
EP3659626A4 (en) MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF CONDITIONS RELATED TO THE TGF- SIGNALING ROUTE, AND ITS APPLICATION
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
FR3038840B1 (fr) Dispositif de securite pour une seringue d'injection.
WO2015162552A3 (en) Composition for topic use
EP3564373A4 (en) THERAPEUTIC DRUG FOR ALPORT SYNDROME
UA118032U (uk) Фармацевтична композиція
TH1601006837A (th) สารประกอบสำหรับการรักษาโรคกล้ามเนื้อฝ่อจากไขสันหลัง
TH1701002334A (th) โครเมนซึ่งถูกแทนที่และวิธีการใช้

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]